Plasma Protein Therapeutics Market Size, Share, and Trends 2025 to 2034

The Plasma Protein Therapeutics Market is projected to grow from USD 31.07 billion in 2025 to USD 48.43 billion by 2034, at a CAGR of 5.06%. Growth is driven by rising chronic disease prevalence, advancements in purification technologies, and personalized medicine approaches. North America leads, while Asia-Pacific expands rapidly.

Last Updated : June 2025  |  Report Code : 3630  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Plasma Protein Therapeutics Market 

5.1. COVID-19 Landscape: Plasma Protein Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Plasma Protein Therapeutics Market, By Product Type

8.1. Plasma Protein Therapeutics Market Revenue and Volume, by Product Type

8.1.1 Immunoglobulin

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Albumin

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Plasma derived factor VIII

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Plasma Protein Therapeutics Market, By Application

9.1. Plasma Protein Therapeutics Market Revenue and Volume, by Application

9.1.1. Hemophilia

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Idiopathic thrombocytopenic purpura

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Primary immunodeficiency disorder

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Others

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Plasma Protein Therapeutics Market, By End-user 

10.1. Plasma Protein Therapeutics Market Revenue and Volume, by End-user

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Others

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Plasma Protein Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product Type

11.1.2. Market Revenue and Volume Forecast, by Application

11.1.3. Market Revenue and Volume Forecast, by End-user

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product Type

11.1.4.2. Market Revenue and Volume Forecast, by Application

11.1.4.3. Market Revenue and Volume Forecast, by End-user

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product Type

11.1.5.2. Market Revenue and Volume Forecast, by Application

11.1.5.3. Market Revenue and Volume Forecast, by End-user

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product Type

11.2.2. Market Revenue and Volume Forecast, by Application

11.2.3. Market Revenue and Volume Forecast, by End-user

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product Type

11.2.4.2. Market Revenue and Volume Forecast, by Application

11.2.4.3. Market Revenue and Volume Forecast, by End-user

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product Type

11.2.5.2. Market Revenue and Volume Forecast, by Application

11.2.5.3. Market Revenue and Volume Forecast, by End-user

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product Type

11.2.6.2. Market Revenue and Volume Forecast, by Application

11.2.6.3. Market Revenue and Volume Forecast, by End-user

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product Type

11.2.7.2. Market Revenue and Volume Forecast, by Application

11.2.7.3. Market Revenue and Volume Forecast, by End-user

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product Type

11.3.2. Market Revenue and Volume Forecast, by Application

11.3.3. Market Revenue and Volume Forecast, by End-user

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product Type

11.3.4.2. Market Revenue and Volume Forecast, by Application

11.3.4.3. Market Revenue and Volume Forecast, by End-user

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product Type

11.3.5.2. Market Revenue and Volume Forecast, by Application

11.3.5.3. Market Revenue and Volume Forecast, by End-user

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product Type

11.3.6.2. Market Revenue and Volume Forecast, by Application

11.3.6.3. Market Revenue and Volume Forecast, by End-user

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product Type

11.3.7.2. Market Revenue and Volume Forecast, by Application

11.3.7.3. Market Revenue and Volume Forecast, by End-user

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product Type

11.4.2. Market Revenue and Volume Forecast, by Application

11.4.3. Market Revenue and Volume Forecast, by End-user

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product Type

11.4.4.2. Market Revenue and Volume Forecast, by Application

11.4.4.3. Market Revenue and Volume Forecast, by End-user

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product Type

11.4.5.2. Market Revenue and Volume Forecast, by Application

11.4.5.3. Market Revenue and Volume Forecast, by End-user

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product Type

11.4.6.2. Market Revenue and Volume Forecast, by Application

11.4.6.3. Market Revenue and Volume Forecast, by End-user

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product Type

11.4.7.2. Market Revenue and Volume Forecast, by Application

11.4.7.3. Market Revenue and Volume Forecast, by End-user

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product Type

11.5.2. Market Revenue and Volume Forecast, by Application

11.5.3. Market Revenue and Volume Forecast, by End-user

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product Type

11.5.4.2. Market Revenue and Volume Forecast, by Application

11.5.4.3. Market Revenue and Volume Forecast, by End-user

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product Type

11.5.5.2. Market Revenue and Volume Forecast, by Application

11.5.5.3. Market Revenue and Volume Forecast, by End-user

Chapter 12. Company Profiles

12.1. CSL Limited

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Grifols S.A.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Takeda Pharmaceutical Company Limited

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Octapharma AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Biotest AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Kedrion S.p.A.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Shire (acquired by Takeda)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bio Products Laboratory (BPL)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Kamada Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. China Biologic Products Holdings, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global plasma protein therapeutics market size is expected to increase USD 48.43 billion by 2034 from USD 29.56 billion in 2024.

The global plasma protein therapeutics market will register growth rate of 5.06% between 2025 and 2034.

The major players operating in the plasma protein therapeutics market are CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Biotest AG, Kedrion S.p.A., Shire (acquired by Takeda), Bio Products Laboratory (BPL), Kamada Ltd., China Biologic Products Holdings, Inc., Octapharma Plasma, Inc., Sanquin, LFB S.A., ADMA Biologics, Inc., Bioverativ (acquired by Sanofi), and Others.

The driving factors of the plasma protein therapeutics market are the expanded label claims and technological advancements.

North America region will lead the global plasma protein therapeutics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client